Crinetics Pharmaceuticals Files 8-K

TL;DR

CRNX filed an 8-K on 12/09/24 - check for updates.

AI Summary

On December 9, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided text excerpt.

Why It Matters

This filing signals that Crinetics Pharmaceuticals has made a regulatory disclosure, which could contain important updates for investors regarding the company's financial health or significant business events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate negative or positive financial implications detailed in the provided text.

Key Players & Entities

• Crinetics Pharmaceuticals, Inc. (company) — Registrant
• December 09, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-38583 (identifier) — Commission File Number
• 26-3744114 (identifier) — IRS Employer Identification No.
• 6055 Lusk Boulevard (address) — Address of Principal Executive Offices
• San Diego (location) — City of Principal Executive Offices
• California (location) — State of Principal Executive Offices
• 92121 (zip_code) — Zip Code of Principal Executive Offices
• (858) 450-6464 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

• crnx-20241209.htm (8-K) — 44KB
• crnx-ex99_1.htm (EX-99.1) — 26KB
• 0000950170-24-134342.txt ( ) — 184KB
• crnx-20241209.xsd (EX-101.SCH) — 23KB
• crnx-20241209_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: December 9, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR